Mr. Tom Looby reports

CONAVI MEDICAL HIGHLIGHTS PEER-REVIEWED PUBLICATION DEMONSTRATING ADVANTAGES OF HYBRID IVUS-OCT IMAGING

Conavi Medical Corp. today highlighted the publication of new peer-reviewed research titled "Deep learning-based plaque characterization in hybrid IVUS-OCT images is superior to single-modality deep learning analysis and human experts: head-to-head comparison against histology," published in Cardiovascular Research by the European Society of Cardiology.

The study analyzed IVUS-OCT images and matched histological sections from 10 cadaveric human hearts, demonstrating that a histology-trained hybrid IVUS-OCT deep-learning classifier outperformed single-modality IVUS, single-modality OCT and expert readers in plaque characterization, supporting the clinical and commercial value of a comprehensive hybrid imaging for enhancing treatment planning.

The publication includes contributions from Dr. Brian Courtney, a pioneer in hybrid IVUS-OCT imaging and co-inventor of the foundational hybrid imaging technology that underpins Conavi's platform. Co-authors included imaging experts in Canada, Europe and the United States, as well as artificial intelligence researchers at Queen Mary University of London.

"Peer-reviewed academic research continues to reinforce the clinical value proposition behind Conavi's technology platform," said Tom Looby, chief executive officer of Conavi Medical. "As the field moves toward more precise, image-guided coronary interventions, research highlighting the complementary strengths of IVUS and OCT underscores the importance of comprehensive hybrid systems."

Conavi is advancing the development and commercialization of its next-generation hybrid IVUS-OCT imaging solutions and has submitted its next-generation Novasight imaging system to the U.S. Food and Drug Administration (FDA) for regulatory clearance, while continuing preparations to support commercialization and clinical adoption.

Stock option grant

The company also announced that it has granted stock options to Mark Quick, chief financial officer, on Feb. 10, 2026. As part of its long-term incentive program, the company granted options to purchase a total of one million common shares at an exercise price equal to the five-day volume-weighted average trading price (VWAP) of the shares on the date of grant, being 41 cents per share. The options vest in accordance with the company's stock option plan and expire 10 years from the date of grant.

The grant of these options remains subject to all necessary regulatory approvals.

About Conavi Medical Corp.

Conavi Medical is focused on designing, manufacturing and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid system is the first to combine intravascular ultrasound (IVUS) and optical coherence tomography (OCT) into a single device, enabling simultaneous and co-registered imaging of coronary arteries. The first-generation Novasight Hybrid system has 510(k) regulatory clearance in the United States, Canada, China and Japan.

We seek Safe Harbor.